SCHEMBL13304413

SCHEMBL13304413

Cc1ccc2c(=O)o[nH]c2c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 3/20 0.43
▸ NOS1 P29475 2/20 0.43
▸ NOS3 P29474 1/20 0.43
▸ NOS2 P35228 1/20 0.43
▸ KIF11 P52732 2/20 0.41
▸ ALDH1A1 P00352 3/20 0.40
▸ KDM4E B2RXH2 2/20 0.40
▸ MAPT P10636 2/20 0.40
▸ CA12 O43570 1/20 0.40
▸ CA9 Q16790 1/20 0.40
▸ RXFP1 Q9HBX9 1/20 0.39
▸ GAA P10253 1/20 0.37
▸ HPGD P15428 1/20 0.37
▸ HSD17B10 Q99714 1/20 0.37
▸ TP53 P04637 1/20 0.37
▸ DAO P14920 2/20 0.37
▸ ELANE P08246 1/20 0.37
▸ DDO Q99489 1/20 0.37
▸ CHEK1 O14757 1/20 0.37
▸ PARP1 P09874 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14644670 0.84 ALDH1A1 (0.47) LMNANOS1NOS3NOS2ALDH1A1
SCHEMBL10780015 0.76 DAO (0.52) LMNANOS1NOS3NOS2ALDH1A1
SCHEMBL29442197 0.73 NOS1 (0.62) LMNANOS1NOS3NOS2KIF11
SCHEMBL3435898 0.73 NOS1 (0.62) LMNANOS1NOS3NOS2KIF11
SCHEMBL29440558 0.70 F2 (0.52) LMNAALDH1A1KDM4EMAPTCA12
SCHEMBL12806101 0.70 — —
SCHEMBL158747 0.70 F2 (0.52) LMNAALDH1A1KDM4EMAPTCA12
SCHEMBL9571854 0.69 MEN1 (0.65) LMNANOS1NOS3NOS2KIF11
Methane SCHEMBL29008285 0.68 F2 (0.50) LMNAALDH1A1KDM4EMAPTCA12
SCHEMBL1100359 0.68 DAO (0.61) LMNANOS1NOS3NOS2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8410152-B2 Thiazolhydrazides for treatment of neurodegenerative diseases MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E. V. (DE) 2013-04-02 — — US disclosed
US-20100151064-A1 THIAZOLHYDRAZIDES FOR TREATMENT OF NEURODEGENERATIVE DISEASES TECHNISCHE UNIVERSITAT DARMSTADT (DE) 2010-06-17 — — US disclosed
US-20100151064-A1 THIAZOLHYDRAZIDES FOR TREATMENT OF NEURODEGENERATIVE DISEASES TECHNISCHE UNIVERSITAT DARMSTADT (DE) 2010-06-17 — — US disclosed
WO-2008052804-A1 THIAZOLHYDRAZIDES FOR TREATMENT OF NEURODEGENERATIVE DISEASES MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2008-05-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100151064-A1 THIAZOLHYDRAZIDES FOR TREATMENT OF NEURODEGENERATIVE DISEASES HTT, MAPT, SNCA LMNA 2315/4885NOS1 4388/4885NOS3 3645/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback